Variables | Overall cohort (n = 103) | Scanner Optima CT660 (n = 50) | Scanner DiscoveryCT750 HD (n = 53) | p value (scanner) | Tube voltage 120 kVp (n = 51) | Tube voltage 100 kVp (n = 52) | p value (kVp) |
---|---|---|---|---|---|---|---|
Gender | |||||||
 Male  Female | 59 (57%) 44 (43%) | 28 (56%) 22 (44%) | 31 (58%) 22 (42%) | 0.798a | 33 (65%) 18 (35%) | 26 (50%) 26 (50%) | 0.131a |
Age | |||||||
 Mean (median)  IQR | 69.2 (70) (64–75) | 69.4 (70) (65–75.3) | 68.9 (69) (62–74.5) | 0.498c | 69.8 (70) (64–76) | 68.6 (68.5) (62–74.8) | 0.251c |
Side  Right  Left | 60 (58%) 43 (42%) | 31 (62%) 19 (38%) | 29 (55%) 24 (45%) | 0.454a | 31 (61%) 20 (39%) | 29 (56%) 23 (44%) | 0.606a |
Position  Upper  Medium  Lower  Mixed | 63 (64%) 1 (1%) 29 (30%) 5 (5%) | 33 (69%) 1 (2%) 13 (27%) 1 (2%) | 30 (60%) 0 (0%) 16 (32%) 4 (8%) | 0.360b | 30 (61%) 1 (2%) 16 (33%) 2 (4%) | 33 (67%) 0 (0%) 13 (27%) 3 (6%) | 0.731b |
Volume (cm3) | |||||||
 Mean (median)  IQR | 46.4 (39.1) (19.1–62.8) | 44.2 (40.6) (19–54.7) | 48.5 (38.1) (19.5–71.9) | 0.843c | 52.1 (42) (20.7–67.9) | 40.9 (36.7) (18.4–56.2) | 0.181c |
Histological type | |||||||
 Adenocarcinoma  Squamous cell carcinoma  Neuroendocrine | 83 (82%) 16 (16%) 2 (2%) | 38 (78%) 10 (20%) 1 (2%) | 45 (87%) 6 (11%) 1 (2%) | 0.580b | 40 (78%) 9 (18%) 2 (4%) | 43 (86%) 7 (14%) 0 (0%) | 0.380b |
Previous therapy | |||||||
 No  Yes | 75 (74%) 26 (26%) | 38 (76%) 12 (24%) | 37 (73%) 14 (27%) | 0.692a | 33 (66%) 17 (34%) | 42 (82%) 9 (18%) | 0.060a |
Scanner | |||||||
 Optima CT660  Discovery CT750 HD | 50 (49%) 53 (51%) | – | – | – | 25 (49%) 26 (51%) | 25 (48%) 27 (52%) | 0.924a |
Tube voltage (kVp) | |||||||
 120  100 | 51 (50%) 52 (50%) | 25 (50%) 25 (50%) | 26 (49%) 27 (51%) | 0.924a | – | – | – |